Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer

被引：0

作者：

Pinto, L. Masfarre ^{[1
]}

Parreira, A. S. D. F. M. ^{[2
]}

Unanua, N. Castro ^{[3
]}

Rocha, P. ^{[4
]}

Ruiz, I. Morilla ^{[5
]}

Sanchez, L. Teijeira ^{[5
]}

Clave, S. ^{[6
]}

Gorro, N. Navarro ^{[7
]}

Mora, R. Bach ^{[8
]}

Sanchez, I. ^{[6
]}

Campos, M. A. Galindo ^{[9
]}

Garcia, A. Taus ^{[10
]}

Martinez, A. Azkarate ^{[11
]}

Fabregat, R. Marse ^{[12
]}

Paricio, B. Bellosillo ^{[13
]}

Arasanz, H. ^{[14
]}

Aguillo, M. Martinez ^{[5
]}

Arriola, E. ^{[7
]}

机构：

[1] Hosp Mar Parc Salut Mar, Dept Oncol, Barcelona, Spain

[2] Hosp Univ son Espases, Med Oncol, Palma de Mallorca, Spain

[3] Hosp Univ Navarra, Oncobiona Med Oncol Dept, Pamplona, Spain

[4] IMIM Inst Hosp Mar dInvest Med, Canc Res Program, Barcelona, Spain

[5] Complejo Hosp Navarra, Dept Oncol, Royal Navarre Hosp, Pamplona, Spain

[6] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain

[7] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[8] Parc Salut Mar, Dept Oncol, Barcelona, Spain

[9] IMIM Inst Hosp Mar dInvest Med, Doctor Aiguader 88, Barcelona, Spain

[10] Hosp Mar Parc Salut Mar, Med Oncol, Barcelona, Spain

[11] Hosp Univ Son Espases, Dept Med Oncol, Palma de Mallorca, Spain

[12] Hosp Univ Son Espases, Dept Oncol, Palma de Mallorca, Spain

[13] Hosp Mar Parc Salut Mar, Mol Biol Dept, Barcelona, Spain

[14] Complejo Hosp Navarra, Dept Med Oncol, Royal Navarre Hosp, Pamplona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2440

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1408P

引用

页数：2

共 50 条

[1] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
Notario Rincon, L.
Pous, A.
Lopez-Paradis, A.
Cerda, G.
Cucurull, M.
Hernandez, A.
Domenech, M.
Carcereny, E.
Moran Bueno, M. T.
Munoz, A.
Mate, J. L.
Sanz, C.
Saigi, M.
ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
[2] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
Pinto, L. Masfarre
Rocha, P.
Clave, S.
Gorro, N. Navarro
Sanchez, I.
Giner, M.
Lloret, A. Corbera
Garcia, A. Taus
Parreira, A. S. D. F. M.
Paricio, B. Bellosillo
Arriola, E.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
[3] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
Marinelli, D.
Pisegna, S.
Giammaruco, M.
Chesi, P.
Mammone, G.
Ceddia, S.
Gazzaniga, P.
Cortesi, E.
Gelibter, A. J.
ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
[4] KRAS G12C mutations in non-small cell lung cancer
Li, J. J.
Wu, X. J.
Farzin, M.
Bray, V.
Williamson, J.
Pal, A.
Yip, P. Y.
Hagelamin, A.
Ding, P.
Nindra, U.
Vinod, S.
French, B.
Chua, W.
Gupta, R.
Cooper, W. A.
Wang, B.
Lee, C. S.
HISTOPATHOLOGY, 2024, 85 : 25 - 25
[5] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico
Ilaria Ricciotti
Valentina Favorito
Sandra Vietti Michelina
Pietro Scaparone
Giulio Metro
Andrea De Giglio
Federica Pecci
Giuseppe Lamberti
Chiara Ambrogio
Biagio Ricciuti
Current Oncology Reports, 2023, 25 : 1017 - 1029
[6] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Di Federico, Alessandro
Ricciotti, Ilaria
Favorito, Valentina
Michelina, Sandra Vietti
Scaparone, Pietro
Metro, Giulio
De Giglio, Andrea
Pecci, Federica
Lamberti, Giuseppe
Ambrogio, Chiara
Ricciuti, Biagio
CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 1017 - 1029
[7] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
Pellini, B.
Ganesan, V.
Wan, F.
Sankararaman, S.
Manyanont, S.
Akhave, N.
Baggstrom, M.
Ward, J.
Waqar, S.
Morgensztern, D.
Govindan, R.
Devarakonda, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210
[8] Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
Zheng, Xinting
Luo, Jiamin
Liu, Wei
Ashby, Charles R., Jr.
Chen, Zhe-Sheng
Lin, Lizhu
DRUGS OF TODAY, 2022, 58 (04) : 175 - 185
[9] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
Rosell, R.
Jain, A.
Codony-Servat, J.
Shivamallu, C.
Kollur, S. Prasad
Prasad, A.
Jantus-Lewintre, E.
Ito, M.
Cardona, A. F.
Arrieta, O.
Cao, P.
Cai, X.
Xing, B.
Pedraz-Valdunciel, C.
Dantes, Z.
Sullivan, I.
Aguilar, A.
Molina-Vila, M. A.
Gonzalez-Cao, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
[10] 31507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
Gadgeel, Shirish M.
Miao, Jieling
Riess, Jonathan W.
Mack, Philip C.
Gerstner, Gregory James
Burns, Timothy F.
Taj, Asma
Akerley, Wallace L.
Dragnev, Konstantin H.
Moon, James
Gandara, David R.
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →